Cognetivity To Assist In Effective Delivery Of Recently Approved Alzheimer’s Drugs

Cognetivity Neurosciences (CSE: CGN) is set to benefit from a recent ruling by the Centers for Medicare and Medicaid Services, which has committed to providing coverage for fully approved FDA treatments for Alzheimer’s.

Medicare has agreed to cover drugs that may slow the progression of Alzheimer’s disease on the condition that the physician and clinical team prescribing such drugs also agree to collect real-world evidence of effectiveness through a registry. Prior to the changes announced on June 1, Medicare only covered such treatments for patients involved in clinical trials.

Cognetivity’s flagship product, CognICA, was demonstrated to be effective in tracking cognitive function in real-world settings during treatment for Alzheimer’s in patients using Aduhelm, a drug developed by Biogen, which was approved by the FDA in June 2021.

“We are thrilled to be in a unique position to play such a pivotal role in the effective targeting and delivery of newly approved Alzheimer’s drugs in the US. Outstanding sensitivity to early-stage disease – the ability to measure small changes in brain function – and the ability to effectively monitor patient progress are CognICA’s greatest strengths, as demonstrated in thousands of patients and numerous peer-reviewed publications,” commented CEO Sina Habibi.

CognICA is said to have screened hundreds of individuals suspected of mild cognitive impairment, and has accurately identified those who need further assessment. Once diagnosed, the platform can be utilized to monitor changes in cognitive function in patients receiving treatment, providing objective, repeatable, and reliable data on the response to treatment by patients.

“CognICA’s continuously learning AI models allow for this challenge to be solved at scale, which will enable payers and providers to roll out these desperately needed treatments with confidence, and then monitor their effectiveness with unprecedented precision, providing valuable insights for clinicians and contributing to the required real-world evidence for coverage,” continued Habibi.

Cognetivity Neurosciences last traded at $0.305 on the CSE.


Information for this briefing was found via Sedar and the sources mentioned. Canacom Group, the parent company of The Deep Dive, is currently long the equity of Cognetivity Neurosciences. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cognetivity Reaches First Commercial Agreement In Middle East

Cognetivity Neurosciences (CSE: CGN) has seen the deployment of its technology to a new region...

Wednesday, September 22, 2021, 09:41:33 AM

Cognetivity Enters Distribution Arrangement For Dementia Product In Middle East

Cognetivity Neurosciences (CSE: CGN) is expanding its global distribution. The firm this morning announced it...

Thursday, January 27, 2022, 09:09:29 AM

Cognetivity Neurosciences Sees Granting Of FDA Clearance For Cognitive Assessment Tool

Cognetivity Neurosciences (CSE: CGN) has reached a major achievement. The company has been granted FDA...

Wednesday, October 20, 2021, 09:22:23 AM

Cognetivity Partners With UK National Health Service For New Remote Brain Health Clinic

Cognetivity Neuroscience (CSE: CGN) this morning indicated that it continues to see adoption of its...

Wednesday, July 14, 2021, 09:25:00 AM

Cognetivity Neurosciences Selected For Accelerator Program To Fast Track US Commercialization

Cognetivity Neurosciences (CSE: CGN) has been selected as one of just seven members of the...

Wednesday, December 23, 2020, 09:08:31 AM